Hatim Kerniss

Dr. Hatim Kerniss

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
JSJohannes Schmucker
Johannes Schmucker
HKHatim Kerniss
Hatim Kerniss
UHUlrich Hanses
Ulrich Hanses
SRStephan Rühle
Stephan Rühle
LMLuis Alberto Mata Marín
Luis Alberto Mata Marín
HWHarm Wienbergen
Harm Wienbergen
Aims: This study aimed to determine the prevalence of severe obesity [body mass index (BMI) ≥ 40 kg/m²] among patients with ST-elevation myocardial infarction (STEMI) and clarify its association with age, temporal trends, and outcomes. Methods and results: Consecutive patients admitted to a German heart centre between 2006 and 2022 for STEMI were categorized into five BMI groups according to the World Health Organization classification. Among the 11 629 STEMI patients, 269 (2.3%) had severe obesity. These patients were more likely to be female, have diabetes, and were on average 8.6 years younger than normal-weight patients (57.8 ± 12 vs. 66.4 ± 14 years, P < 0.01). The prevalence of severe obesity increased from 1.9 to 2.6% (2006–13 vs. 2013–22, P = 0.014), with the increase being a greater in females than in males (2.5–3.7%, P = 0.052). In younger patients (<55 years), prevalence rates increased by 128% in females (4.9–11.3%, P < 0.01) and 71% in men (2.2–3.7%, P < 0.01). Severe obesity did not affect treatment outcomes or in-hospital adverse event rates but was associated with higher 30-day [14.2% vs. 9.2%; adjusted hazard ratio (HR), 1.99; 95% confidence interval (CI), 1.4–3.0; P < 0.01] and 5-year mortality rates (30.6% vs. 20.6%; adjusted HR, 2.03; 95% CI, 1.4–2.9; P < 0.01). Conclusion: The significant increase in the prevalence of severe obesity among patients with STEMI, particularly among females and younger individuals, underscores the urgent need for more effective prevention and treatment strategies to improve their long-term prognosis.

9 July 2026 in EBioMedicine
Verified
Journal Article
Open access
HKHatim Kerniss
Hatim Kerniss
PCPhilip Curman
Philip Curman
HOHenning Olbrich
Henning Olbrich
KKKhalaf Kridin
Khalaf Kridin
RFRohin Francis
Rohin Francis
RLRalf J. Ludwig
Ralf J. Ludwig
Testosterone therapy (TT) is increasingly initiated outside classical hypogonadism, but long-term cardiovascular safety in this context remains uncertain. We assessed whether TT initiation without evidence of hypogonadism is associated with higher long-term cardiovascular risk than TT initiation with evidence of hypogonadism. In this global retrospective real-world cohort study, men aged 30-75 years initiating TT were identified from secondary, de-identified structured EHR data from 123 healthcare organisations. A prespecified 3-year pre-index washout excluded prior TT and major cardiovascular/thromboembolic events. Men initiating TT without evidence of hypogonadism were compared with those with evidence of hypogonadism using 1:1 propensity-score matching. The primary outcome was major adverse cardiovascular events (MACE); secondary outcomes included separately all-cause mortality, myocardial infarction, ischaemic stroke, cardiac arrest, and heart failure. Acute appendicitis served as a negative-control outcome. Among 358,957 TT initiators, 127,152 (35.4%) had no evidence of hypogonadism. After matching, 113,554 pairs were followed for up to 10 years. TT without evidence of hypogonadism was associated with higher risk of MACE (16.53% vs 11.83%; HR 1.51, 1.45-1.56) and all-cause mortality (HR 1.90, 1.79-2.00), with higher risks of ischaemic stroke (HR 1.23, 1.14-1.33), cardiac arrest (HR 1.41, 1.23-1.61), and heart failure (HR 1.32, 1.26-1.39). Race-stratified estimates were directionally consistent but varied in magnitude. The cardiovascular safety of TT appears context-dependent and less favourable when treatment is initiated without evidence of hypogonadism, with clinically relevant heterogeneity across race/ethnicity, supporting biologically informed prescribing and cardiovascular risk surveillance. Deutsche Forschungsgemeinschaft, Schleswig-Holstein Excellence-Chair Program, and Region Stockholm.

4 June 2026 in Atherosclerosis
Verified
Journal Article
Open access
HKHatim Kerniss
Hatim Kerniss
HOHenning Olbrich
Henning Olbrich
PCPhilip Curman
Philip Curman
SSSascha Ständer
Sascha Ständer
KKKhalaf Kridin
Khalaf Kridin
RLRalf J. Ludwig
Ralf J. Ludwig
Systemic inflammation contributes to atherosclerosis and its thrombotic complications, yet population-level data for neutrophil-predominant dermatoses are limited. Pyoderma gangrenosum (PG) is a prototypical neutrophilic inflammatory dermatosis, we quantified its association with incident atherothrombotic events and MACE over 5 years. Adults with PG were compared with non-PG controls. To limit reverse causation, we excluded individuals with pre-index cardiovascular events and selected vascular procedures. Cohorts were 1:1 propensity-score matched (greedy nearest neighbor; caliper 0.1 SD of logit). Follow-up was up to 5 years. Primary endpoint was MACE (cardiac arrest, cardiogenic shock, acute myocardial infarction [MI], ischemic stroke, all-cause mortality). Secondary endpoints were MI, ischemic stroke, symptomatic peripheral artery disease (PAD), and all-cause mortality. A negative-control outcome and a procedure-anchored PAD sensitivity analysis (lower-extremity revascularization) were prespecified. Among 10,669 PG patients and 2,908,830 controls, 10,666 matched pairs were retained with good covariate balance. Over 5 years, PG was associated with higher risk of MACE (HR 1.32; p < 0.001), MI (HR 1.42; p = 0.001), and all-cause mortality (HR 1.44; p < 0.001), while ischemic stroke was neutral (HR 0.94; p = 0.52). Symptomatic PAD showed the largest association (HR 5.48; p < 0.001), confirmed in the procedure-anchored analysis (HR 5.58; p < 0.0001). The negative control was null (HR 1.04; p = 0.82). PG is associated with meaningful excess atherothrombotic risk, particularly PAD, supporting PG as a systemic inflammatory risk-enhancing condition requiring intensified cardiovascular prevention.

27 February 2026 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HKHatim Kerniss
Hatim Kerniss
UHUlrich Hanses
Ulrich Hanses
SRStephan Rühle
Stephan Rühle
AFAndreas Fach
Andreas Fach
JSJohannes Schmucker
Johannes Schmucker
RHRainer Hambrecht
Rainer Hambrecht


10 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
HKHatim Kerniss
Hatim Kerniss
PCPhilip Curman
Philip Curman
SFSophie von Fritsch
Sophie von Fritsch
SPSee Pdf
See Pdf
Background: Evidence regarding patent foramen ovale (PFO) in pregnancy is largely limited to case reports, and the population-level risk associated with isolated, uncomplicated PFO remains ill-defined. This population-based study assessed the maternal thromboembolic risk associated with isolated uncomplicated PFO.Methods: Pregnant women with pre-existing isolated PFO and no previous cardiovascular or embolic events were compared with pregnant women without a diagnosis of PFO. Cohorts were balanced by a comprehensive 1:1 propensity-score matching (PSM). The primary outcome was 1-year major adverse cardiovascular and cerebrovascular events (MACCE: all-cause mortality, myocardial infarction, or ischaemic stroke). Key secondary outcomes were cerebral ischaemic events and a systemic embolic composite. Prespecified analyses included temporal and exclusion sensitivity analyses, multivariable Cox modelling, a within-PFO pregnancy-context analysis, and a negative-control outcome.Findings: 415 848 pregnant women were included: 3717 with pre-existing isolated PFO and 412 131 without diagnosed PFO. 3715 pairs remained after matching. At 1 year, MACCE occurred in 3.9% of women with PFO and 1.5% of controls (HR 2.72, 95% CI 1.87–3.93; p<0·0001). Excess risk was concentrated in thromboembolic outcomes: cerebral ischaemic events (3.8% vs 0.5%; HR 7·68, 4.43–13.31; p<0.0001) and the systemic embolic composite (4.4% vs 0.7%; HR 5.97, 3.76–9.51; p<0.0001). Findings were consistent across robustness analyses; the negative-control outcome was neutral. Among women with isolated PFO, pregnancy itself was independently associated with increased thromboembolic risk (MACCE: HR 3.17, cerebral ischaemic events: HR 3.07 and systemic embolization: HR 2.86, all p<0.0001). Negative-control outcomes were consistently neutral.Interpretation: PFO was associated with excess maternal thromboembolic risk, driven predominantly by cerebral ischaemic and systemic embolic events. These findings support heightened surveillance and prospective evaluation of management strategies in women with PFO who are pregnant or planning pregnancy.